Function and regulation of the β3-adrenoceptor

doi:10.1016/S0165-6147(96)80011-3

Trends in Pharmacological Sciences

Volume 17, Issue 10, October 1996, Pages 373-381

https://doi.org/10.1016/S0165-6147(96)80011-3 Get rights and content

Abstract

The cloning, sequencing and expression in model systems of the previously unidentified β₃-adrenoceptor recently led to an extensive functional characterization. Ligand binding and adenylate cyclase activation studies helped define a specific profile that is quite distinct from that of the β₁- and β₂-adrenoceptors, but strongly reminiscent of most of the ‘atypical’ β-adrenoceptor-mediated responses reported in earlier pharmacological studies. More recently, a naturally occurring variation in the human β₃-adrenoceptor has been correlated with hereditary obesity and with increased dynamic capacity to add on weight and develop non-insulin dependent diabetes in Western obese patients. Donny Strosberg and France Pietri-Rouxel describe how results now provide a consistent picture of an important role for the human β₃-adrenoceptor in the regulation of lipid metabolism and as an obvious target for drugs to treat some forms of obesity and diabetes.

References (64)

P. Muzzin
J. Biol. Chem.
(1991)
A. Méjean et al.
Eur. J. Pharmacol.
(1995)
B. Fève
J. Biol. Chem.
(1991)
L.J. Emorine et al.
Trends Pharmacol. Sci.
(1994)
M. Moinat
FEBS Lett.
(1995)
E.M. Rohlfs et al.
J. Biol. Chem.
(1995)
F. Nantel et al.
J. Biol. Chem.
(1994)
R. Jockers et al.
J. Biol. Chem.
(1996)
M. Lafontan et al.
J. Lipid Res.
(1993)
V.S. Susulic
J. Biol. Chem.
(1995)

L.A. Tartaglia

Cell

(1995)

B. Fève

J. Biol. Chem.

(1990)

B. Fève

J. Biol. Chem.

(1992)

S. Krief

J. Biol. Chem.

(1994)

B. Fève et al.

J. Biol. Chem.

(1995)

J.R.S. Arch

Nature

(1984)

D. Bojanic et al.

Br. J. Pharmacol.

(1985)

J.R.S. Arch et al.

Med. Res. Rev.

(1993)

L.J. Emorine

Science

(1989)

C. Nahmias

EMBO J.

(1991)

J.G. Granneman et al.

Mol. Pharmacol.

(1991)

F. Piétri-Rouxel

Eur. J. Biochem.

(1995)

R.A.J. Challis et al.

Biochem. Pharmacol.

(1988)

A.I. Kaumann

Br. J. Pharmacol.

(1996)

C. Gauthier et al.

J. Clin. Invest.

(1996)

N. Blin et al.

Mol. Pharmacol.

(1993)

J.A. Dolan

J. Pharmacol. Exp. Ther.

(1994)

A.D. Strosberg

Protein Sci.

(1993)

N. Blin et al.

Br. J. Pharmacol.

(1994)

K.M. Tate

Eur. J. Biochem.

(1991)

O. Marko et al.

Endocrinology

(1995)

S. Krief

J. Clin. Invest.

(1993)

Cited by (171)

The β3 adrenoceptor in proliferative retinopathies: “Cinderella” steps out of its family shadow
2023, Pharmacological Research
In the retina, hypoxic condition leads to overgrowing leaky vessels resulting in altered metabolic supply that may cause impaired visual function. Hypoxia-inducible factor-1 (HIF-1) is a central regulator of the retinal response to hypoxia by activating the transcription of numerous target genes, including vascular endothelium growth factor, which acts as a major player in retinal angiogenesis. In the present review, oxygen urge by the retina and its oxygen sensing systems including HIF-1 are discussed in respect to the role of the beta-adrenergic receptors (β-ARs) and their pharmacologic manipulation in the vascular response to hypoxia. In the β-AR family, β1- and β2-AR have long been attracting attention because their pharmacology is intensely used for human health, while β3-AR, the third and last cloned receptor is no longer increasingly emerging as an attractive target for drug discovery. Here, β3-AR, a main character in several organs including the heart, the adipose tissue and the urinary bladder, but so far a supporting actor in the retina, has been thoroughly examined in respect to its function in retinal response to hypoxia. In particular, its oxygen dependence has been taken as a key indicator of β3-AR involvement in HIF-1-mediated responses to oxygen. Hence, the possibility of β3-AR transcription by HIF-1 has been discussed from early circumstantial evidence to the recent demonstration that β3-AR acts as a novel HIF-1 target gene by playing like a putative intermediary between oxygen levels and retinal vessel proliferation. Thus, targeting β3-AR may implement the therapeutic armamentarium against neovascular pathologies of the eye.
α<inf>1</inf>-adrenoceptor activity of β-adrenoceptor ligands – An expected drug property with limited clinical relevance
2020, European Journal of Pharmacology
Citation Excerpt :
Radioligand binding to rat brain α1-adrenoceptors was inhibited with a pKi of 6.25 (Brahmadevara et al., 2004) or 6.6 (Leblais et al., 2004). Alprenolol is a β-adrenoceptor antagonist with comparable affinity for β1-and β2-adrenoceptors and some selectivity over β3-adrenoceptors (Baker, 2005; Blin et al., 1994; Hoffmann et al., 2004; Strosberg and Pietri-Rouxel, 1996). Alprenolol was reported to inhibit phenylephrine-induced contraction of rat aorta (pEC50 5.10) (Brahmadevara et al., 2003) and binding to rat brain α1-adrenoceptors (pKi of 5.90) (Brahmadevara et al., 2004).
Many β-adrenoceptor agonists and antagonists including several clinically used drugs have been reported to also exhibit binding to α₁-adrenoceptors. Such promiscuity within the adrenoceptor family appears to occur more often than off-target effects of drugs in general. It should not be considered surprising based on the amino acid homology among the nine adrenoceptor subtypes including the counter-ions for binding the endogenous catecholamines. When β-adrenoceptor ligands also bind to α₁-adrenoceptors, they almost always act as antagonists, regardless of being agonists or antagonists at the β-adrenoceptor. The α₁-adrenoceptor affinity of β-adrenoceptor ligands in most cases is at least one, and often more log units lower than at their cognate receptor. Consistent evidence from multiple investigators indicates that β-adrenoceptor ligands relatively have the highest affinity for α_1A- and lowest for α_1B-adrenoceptors. While promiscuity among adrenoceptor subtypes causes misleading interpretation of experimental in vitro data, it is proposed based on the law of mass action that α₁-adrenoceptor binding of β-adrenoceptor ligands rarely contributes to the clinical profile of such drugs, particularly if they are agonists at the β-adrenoceptor.
Physiology and pathophysiology of the β <inf>3</inf> -adrenergic receptor
2019, Progress in Molecular Biology and Translational Science
The β₃-adrenergic receptor (β₃-AR) is an important regulator of various physiological functions, such as thermogenesis in brown adipose tissue, lipolysis in white adipose tissue, negative inotropic effect in cardiomyocyte, and relaxation in blood vessel. The activation of β₃-AR by its agonists is shown to have metabolic (antiobesity and antidiabetic) and cardiovascular effects in animal models, highlighting β₃-AR as a potential therapeutic target in the treatment of several human diseases. Moreover, a substantial number of studies performed on different populations have identified some β₃-AR polymorphic variants associated with obesity, diabetes, cardiovascular diseases, and other disorders. The clinical phenotypes and functional characteristics of these variants provide insights into potential pathophysiological roles of β₃-AR in the development of these diseases.
β<inf>3</inf> adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function
2016, Kidney International
Citation Excerpt :
The present results show β3-AR expression in the same AVPR2-expressing tubules. Because it is known that, similar to AVPR2, β3-AR activates the cAMP pathway,32 we hypothesized that pharmacologic stimulation of β3-AR might regulate the trafficking/activity of AQP2 and NKCC2 involved in the AVP-elicited antidiuresis in the kidney.2,3 We first demonstrated that BRL37344 significantly increases cAMP production and promotes both AQP2 apical accumulation and NKCC2 phosphorylation/activation, suggesting that, similar to AVP, β3-AR agonists may increase reabsorption of water and solutes in the kidney.
To date, the study of the sympathetic regulation of renal function has been restricted to the important contribution of β₁- and β₂-adrenergic receptors (ARs). Here we investigate the expression and the possible physiologic role of β₃-adrenergic receptor (β₃-AR) in mouse kidney. The β₃-AR is expressed in most of the nephron segments that also express the type 2 vasopressin receptor (AVPR2), including the thick ascending limb and the cortical and outer medullary collecting duct. Ex vivo experiments in mouse kidney tubules showed that β₃-AR stimulation with the selective agonist BRL37344 increased intracellular cAMP levels and promoted 2 key processes in the urine concentrating mechanism. These are accumulation of the water channel aquaporin 2 at the apical plasma membrane in the collecting duct and activation of the Na-K-2Cl symporter in the thick ascending limb. Both effects were prevented by the β₃-AR antagonist L748,337 or by the protein kinase A inhibitor H89. Interestingly, genetic inactivation of β3-AR in mice was associated with significantly increased urine excretion of water, sodium, potassium, and chloride. Stimulation of β3-AR significantly reduced urine excretion of water and the same electrolytes. Moreover, BRL37344 promoted a potent antidiuretic effect in AVPR2-null mice. Thus, our findings are of potential physiologic importance as they uncover the antidiuretic effect of β₃-AR stimulation in the kidney. Hence, β₃-AR agonism might be useful to bypass AVPR2-inactivating mutations.
Adrenergic signaling in teleost fish liver, a challenging path
2016, Comparative Biochemistry and Physiology Part - B: Biochemistry and Molecular Biology
Citation Excerpt :
Nickerson et al. (2003) first reported a paralogue within the β3-AR subtype which they called β3a- and β3b-ARs. Phylogenetic analysis indicated that both were homologues of the mammalian β3-ARs although their tissue distribution and possible function were totally different from the mammalian (rodent) β3-AR orthologue which at the time was considered to be found primarily in adipose tissue and to function in adrenergic regulation of energy metabolism and thermogenesis (Strosberg and Pietri-Rouxel, 1996). These trout β3-ARs showed an 84% sequence identity to each other although an additional of 48 amino acids was identified in the cytoplasmic tail of the β3b- relative to the β3a-ARs.
Adrenergic receptors or adrenoceptors (ARs) belong to the huge family of G-protein coupled receptors (GPCRs) that have been well characterized in mammals primarily because of their importance as therapeutic drug targets. ARs are found across vertebrates and this review examines the path to identify and characterize these receptors in fish with emphasis on hepatic metabolism. The absence of reliable and specific pharmacological agents led investigators to define the fish hepatic AR system as relying solely on a β₂-AR, cAMP-dependent signaling transduction pathway. The use of calcium-radiometric imaging, purified membranes for ligand-binding studies, and perifused rather than static cultured fish hepatocytes, unequivocally demonstrated that both α₁- and β₂-AR signaling systems existed in the fish liver consistent with studies in mammals. Additionally, the use of molecular tools and phylogenetic analysis clearly demonstrated the existence of multiple AR-types and -subtypes in hepatic and other tissues of a number of fish species. This review also examines the use of β-blockers as pharmaceuticals and how these drugs that are now in the aquatic environment may be impacting aquatic species including fish and some invertebrates. Clearly there is a large conservation of structure and function within the AR system of vertebrates but there remain a number of key questions that need to be addressed before a clear understanding of these systems can be resolved.
Involvement of β<inf>3</inf>-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [<sup>3</sup>H]-acetylcholine release experiments in the isolated detrusor
2015, European Journal of Pharmacology
Citation Excerpt :
Thus, this suboptimal management calls for the development of superior therapeutics via the discovery of novel receptor targets that differently address the parasympathetic pathway. To this end, recent studies have focused on sympathetic neurotransmission, especially the β-adrenergic receptors (β-ADRs), which are currently classified into three subtypes (β1, β2 and β3) (Bylund et al., 1994; Strosberg and Pietri-Rouxel, 1996). Their expression and relative abundance are documented in the urinary bladder of mammals (Ursino et al., 2009), but interestingly, the stimulation of the predominant β3-subtype (Nomiya and Yamaguchi, 2003; Tyagi et al., 2009) in response to sympathetic nerve activity in the human bladder seems to represent the most relevant mechanism to determine bladder capacity without influencing bladder contraction (Yamaguchi, 2002; Yamanishi et al., 2006; Yamaguchi and Chapple, 2007).
Bladder overactivity (OAB) is a multifactorial bladder disorder that requires therapeutics superior to the current pharmacological treatment with muscarinic antagonists. β₃-adrenoceptor (β₃-ADR) agonists represent a novel promising approach that differently addresses the parasympathetic pathway, but the clinical efficacy of these drugs has not been fully elucidated to date. Therefore, we aimed to study the pharmacological mechanisms activated by β₃-ADR agonists at muscular and neural sites in the isolated human bladder. Detrusor smooth muscle strips obtained from male patients undergoing total cystectomy were labelled with tritiated choline and stimulated with electrical field stimulation (EFS). EFS produced smooth muscle contraction and simultaneous acetylcholine ([³H]-ACh) release, which mostly reflects the neural origin of acetylcholine. Isoprenaline (INA), BRL37344 and mirabegron inhibited the EFS-evoked contraction and [³H]-ACh release in a concentration-dependent manner, yielding concentration–response curves (CRCs) that were shifted to the right by the selective β₃-ADR antagonists L-748,337 and SR59230A. Based on the agonist potency estimates (pEC₅₀) and apparent affinities (pK_b) of antagonists evaluated from the CRCs of agonists, our data confirm the occurrence of β₃-ADRs at muscle sites. Moreover, our data are consistent with the presence of inhibitory β₃-ADRs that are functionally expressed at the neural site. Taken together, these findings elucidate the mechanisms activated by β₃-ADR agonists because neural β₃-ADRs participate in the inhibition of detrusor motor drive by reducing the amount of acetylcholine involved in the cholinergic pathway.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

ReviewFunction and regulation of the β3-adrenoceptor

Abstract

J. Biol. Chem.

Eur. J. Pharmacol.

J. Biol. Chem.

Trends Pharmacol. Sci.

FEBS Lett.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Lipid Res.

J. Biol. Chem.

Cell

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Nature

Br. J. Pharmacol.

Med. Res. Rev.

Science

EMBO J.

Mol. Pharmacol.

Eur. J. Biochem.

Biochem. Pharmacol.

Br. J. Pharmacol.

J. Clin. Invest.

Mol. Pharmacol.

J. Pharmacol. Exp. Ther.

Protein Sci.

Br. J. Pharmacol.

Eur. J. Biochem.

Endocrinology

J. Clin. Invest.

Review
Function and regulation of the β₃-adrenoceptor